Nicole Harrison1, Wolfgang Poeppl2, Manuel Miksch1, Klaus Machold3, Hans Kiener3, Daniel Aletaha3, Josef S Smolen3, Christina Forstner4, Heinz Burgmann1, Heimo Lagler5. 1. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria. 2. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria; Department of Dermatology and Tropical Medicine, Military Medical Cluster East, Austrian Armed Forces, Austria. 3. Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria. 4. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria; Institute of Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany. 5. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria. Electronic address: heimo.lagler@meduniwien.ac.at.
Abstract
BACKGROUND: Patients with inflammatory rheumatic diseases are at higher risk for influenza and current guidelines recommend vaccination for this group of patients. The aim of this study was to evaluate the vaccination coverage and predictors for influenza vaccination among patients with inflammatory rheumatic diseases. METHODS: This survey was conducted at the outpatient rheumatology clinic at the Medical University of Vienna between July and October 2017. All patients diagnosed with an inflammatory rheumatic disease and receiving immunosuppressive therapy were asked to complete a questionnaire about their influenza vaccination status for 2016/17. RESULTS: 490 patients with rheumatic diseases completed a questionnaire (33% male, mean age 55.3 years). The influenza vaccination rate for the previous season was 25.3% (n = 124/490). Predictors for a positive influenza vaccination status were higher age (Adjusted Odds Ratio 5.0, 95% Confidence Interval 2.4-10.4) and treatment with biological disease-modifying antirheumatic drugs (AOR 2.0, 95% CI 1.3-3.1). Patients who received a recommendation for influenza vaccination by their general practitioner were significantly more likely to be vaccinated than those who did not (57% vs. 15%, AOR 6.6, 95% CI 4.1-10.8); even more so if they received a recommendation by their rheumatologist (62% vs. 19%, AOR 9.0, 95% CI 4.9-16.5). The main reasons for patients to decline influenza vaccination were fear of side effects (36%), concerns that vaccination might not be effective due to their immunosuppressed condition (38%) or that it might worsen the rheumatic disease (20%). CONCLUSIONS: A moderate influenza vaccination rate of 25.3% was detected among patients with inflammatory rheumatic diseases. Recommendation of the influenza vaccine by a physician exerts the most effective impact on a positive vaccination status.
BACKGROUND:Patients with inflammatory rheumatic diseases are at higher risk for influenza and current guidelines recommend vaccination for this group of patients. The aim of this study was to evaluate the vaccination coverage and predictors for influenza vaccination among patients with inflammatory rheumatic diseases. METHODS: This survey was conducted at the outpatient rheumatology clinic at the Medical University of Vienna between July and October 2017. All patients diagnosed with an inflammatory rheumatic disease and receiving immunosuppressive therapy were asked to complete a questionnaire about their influenza vaccination status for 2016/17. RESULTS: 490 patients with rheumatic diseases completed a questionnaire (33% male, mean age 55.3 years). The influenza vaccination rate for the previous season was 25.3% (n = 124/490). Predictors for a positive influenza vaccination status were higher age (Adjusted Odds Ratio 5.0, 95% Confidence Interval 2.4-10.4) and treatment with biological disease-modifying antirheumatic drugs (AOR 2.0, 95% CI 1.3-3.1). Patients who received a recommendation for influenza vaccination by their general practitioner were significantly more likely to be vaccinated than those who did not (57% vs. 15%, AOR 6.6, 95% CI 4.1-10.8); even more so if they received a recommendation by their rheumatologist (62% vs. 19%, AOR 9.0, 95% CI 4.9-16.5). The main reasons for patients to decline influenza vaccination were fear of side effects (36%), concerns that vaccination might not be effective due to their immunosuppressed condition (38%) or that it might worsen the rheumatic disease (20%). CONCLUSIONS: A moderate influenza vaccination rate of 25.3% was detected among patients with inflammatory rheumatic diseases. Recommendation of the influenza vaccine by a physician exerts the most effective impact on a positive vaccination status.
Authors: K Lakota; K Perdan-Pirkmajer; S Sodin-Šemrl; S Čučnik; V Šubelj; K Prosenc; K Mrak Poljšak; M Tomšič; A Ambrožič; S Praprotnik Journal: Clin Rheumatol Date: 2019-02-14 Impact factor: 2.980
Authors: Michael Eder; Haris Omic; Jana Gorges; Florian Badt; Zeljko Kikic; Marcus D Saemann; Allison Tong; David Bauer; Georg Semmler; Thomas Reiberger; Heimo Lagler; Bernhard Scheiner Journal: PLoS One Date: 2021-04-13 Impact factor: 3.240
Authors: Gabriel Figueroa-Parra; Andrea Moreno-Salinas; Leticia Santoyo-Fexas; Carmen Magdalena Gamboa-Alonso; Juan Pablo Carrizales-Luna; Ivan de Jesus Hernandez-Galarza; Dionicio Angel Galarza-Delgado; Jorge Antonio Esquivel-Valerio Journal: Reumatologia Date: 2022-01-12
Authors: Sebastian Eduardo Sattui; Jean W Liew; Jonathan S Hausmann; Julia F Simard; Jeffrey A Sparks; Kevin Kennedy; Emily Sirotich; Michael Putman; Tarin T Moni; Akpabio Akpabio; Deshiré Alpízar-Rodríguez; Francis Berenbaum; Inita Bulina; Richard Conway; Aman Dev Singh; Eimear Duff; Karen L Durrant; Tamer A Gheita; Catherine L Hill; Richard A Howard; Bimba F Hoyer; Evelyn Hsieh; Lina El Kibbi; Adam Kilian; Alfred Hyoungju Kim; David F L Liew; Chieh Lo; Bruce Miller; Serena Mingolla; Michal Nudel; Candace A Palmerlee; Jasvinder A Singh; Namrata Singh; Manuel Francisco Ugarte-Gil; John Wallace; Kristen J Young; Suleman Bhana; Wendy Costello; Rebecca Grainger; Pedro M Machado; Philip C Robinson; Paul Sufka; Zachary S Wallace; Jinoos Yazdany; Carly Harrison; Maggie Larché; Mitchell Levine; Gary Foster; Lehana Thabane; Lisa G Rider Journal: RMD Open Date: 2021-09
Authors: Gabriel Figueroa-Parra; Jorge Antonio Esquivel-Valerio; Leticia Santoyo-Fexas; Andrea Moreno-Salinas; Carmen Magdalena Gamboa-Alonso; Ana Laura De Leon-Ibarra; Dionicio Angel Galarza-Delgado Journal: Hum Vaccin Immunother Date: 2020-09-29 Impact factor: 3.452